Next Generation Biologics Market Report 2018-2028: Forecasts by Market and Segments
• Do you need definitive Next Generation Biologics market data?
• Do you want to understand clear demarcation between next generation biologics and traditional biologics?
• Next Generation Biologics and sub-segment market analysis?
• Key drivers and constrains accompanied by this market?
• Clear leaders and lagers?
• Next wave of blockbusters and drivers impacting them?
Read on to discover how this definitive report can transform your own research and save you time.
The introduction of new pipeline drugs in Next generation biologics, has led visiongain to publish this timey report. The Next generation biologics market is expected to flourish in the next few years because of emergence of new phase III as well as marketed candidates which are going change the course of the market. Not only new candidates, but the technology (drug delivery as well as the mechanism of action) are novel which make the report a worth find and insightful.
Report highlights
• 140 quantitative tables, charts, and graphs
• Analysis of key players in Next generation biologics Market
• Abbvie
• Roche/ Genentech
• Amgen
• GSK
• Eli Lilly
• Sanofi Aventis
• Novo Nordisk
• Seattle Genetics
• Global next generation biologics market outlook and analysis from 2018-2028
• Regional Next generation biologics market forecasts from 2018-2028
• US forecast 2018-2028,
• Japan forecast 2018-2028
• India forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• China forecast 2018-2028
• Key questions answered
• What does the future hold for the next generation biologics?
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?
• Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the Next-Generation Biologics Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to Next-Generation Biologics
2.1 Brief History of Biological Drug Development
2.1.1 Limitations of Present-Generation Biological Drugs
2.2 The Promise of Next-Generation Biologics
2.2.1 Defining Next-Generation Biologics
2.2.1.1 A Definition of Regenerative Medicine
2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies
3. World Next-Generation Biologics Market: Outlook and Forecast 2017-2028
3.1 The Next-Generation Biologics Market 2017
3.1.1 Development of the Next-Generation Biologics Market 2009-2016
3.1.2 Rising Demand for Biological Therapies
3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2016
3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
3.1.5 Leading Companies in the Next-Generation Biologics Market 2017
3.2 The Next-Generation Biologics Market 2017-2028
3.2.1 Growth Drivers for Biological Drug Revenues 2017-2028
3.2.2 The Next-Generation Biologics Market Forecast 2017-2028
3.2.3 Product Launches in All Sectors to Drive Market Growth 2017-2028
3.2.4 Next-Generation Biologics: Market Restraints 2017-2028
3.2.5 Rising Market Shares for Next-Generation Insulins 2017-2028
4. Leading National Submarkets for Next-Generation Biologics 2017-2028
4.1 Leading National Submarkets for Next-Generation Biologics, 2017
4.1.1 National Submarket Forecasts 2017-2028
4.1.2 How Will National Submarket Shares Change to 2028?
4.2 Rising Disease Incidence in Important Markets 2017-2028
4.3 Approval of Next-Generation Biologics in Leading National Submarkets
4.4 The US Will be the Largest Submarket for Next-Generation Biologics 2017-2028
4.4.1 US Submarket Forecast 2017-2028
4.5 Next-Generation Biologics in Japan 2017-2028
4.5.1 National Expertise in Stem Cell Research
4.5.2 Japanese Submarket Forecast 2017-2028
4.6 Next-Generation Biologics in Leading EU Countries 2017-2028
4.6.1 Regenerative Medicine Development in the EU
4.6.2 Market Access for Next-Generation Biologics in the EU
4.6.3 Germany: Submarket Forecast 2017-2027
4.6.4 France: Submarket Forecast 2017-2028
4.6.5 UK: Submarket Forecast 2017-2028
4.6.6 Italy and Spain: Submarket Forecasts 2017-2028
4.7 Next-Generation Biologics in Emerging Markets 2017-2028
4.7.1 Next-Generation Biologics Development in Emerging Countries
4.7.2 Chinese Submarket Forecast 2017-2028
4.7.3 Indian Submarket Forecast 2017-2028
5. Next-Generation Antibodies: Submarket Outlooks 2017-2028
5.1 Strategies for Improving Antibody Therapies
5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
5.1.2 Engineering Antibodies for Improved Potency
5.1.3 Bispecific Antibodies
5.2 Next-Generation Antibody Therapy Submarket
5.3 Next-Generation Antibody Therapy Submarket 2017-2028
5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2017-2028
5.3.2 Blockbuster Potential Will Drive Growth to 2028: Kadcyla, Adcetris and Cosentyx
5.3.3 Next-Generation Antibodies: Submarket Restraints 2017-2028
5.4 Antibody-Drug Conjugates (ADC) Submarket 2017-2028
5.4.1 Antibody-Drug Conjugates Submarket Forecast 2017-2028
5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2017-2028
5.4.2 What Will Drive Growth for ACDs to 2028
5.4.3 A Long Pipeline of ADCs in Clinical Development
5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue
5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer
5.4.3.3 IMGN853 (Immunogen): Phase III for Ovarian Cancer
5.4.3.4 SGN-CD33A (Seattle Genetics): Phase III for Acute myeloid leukemia
5.4.3.5 Rova-T (Abbvie): Phase III for SCLC
5.4.3.6 CDX-011: Potential for Accelerated Approval in Breast Cancer
5.5 Engineered Antibodies Submarket 2017-2028
5.5.1 Engineered Antibodies Submarket Forecast 2017-2028
5.5.1.1 Gazvya Will Lead the Submarket in 2028
5.5.2 Portfolio Management to Drive Growth 2017-2028
5.5.3 Engineered Antibodies Pipeline 2016
5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
5.6 Bispecific Antibodies Submarket 2017-2028
5.6.1 Bispecific Antibodies Submarket Forecast 2017-2028
5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2017-2028
5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2016
5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody
6. Antibody Fragments and Novel Antibody-like Drugs: Commercial Potential 2017-2028
6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
6.1.1 Antibody-Like Proteins Mimic Antibody Therapies
6.1.2 There are Advantages to Using Fragments and Novel Scaffolds
6.2 Antibody Fragment and ALP Submarket 2017-2028
6.2.1 Antibody Fragment and ALP Submarket Forecast 2017-2028
6.2.2 Pharma is Investing Strongly in Antibody Fragments and ALPs
6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2028
6.3 Outlook for Next-Generation Antibody Fragments 2017-2028
6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2017-2028
6.3.2 One Platform Leads the Pipeline in 2016
6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
6.4 The Antibody-Like Protein Submarket 2017-2028
6.4.1 Antibody-Like Protein Submarket Forecast 2017-2028
6.4.2 Four ALPs in Clinical Development in 2017
6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed
6.5 Will Next-Generation Immunotoxins Change the Market to 2028?
6.5.1 Challenges with First Generation Immunotoxins
6.5.2 Fusion Protein Conjugates: Pipeline 2016
6.5.2.1 Moxetumomab Pasudotox
6.5.3 Humanised Immunotoxins
6.5.3.1 Using Granzyme B in Immunotoxins
6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins
7. Next-Generation Insulin Submarket: Outlook 2017-2028
7.1 Strategies for Next-Generation Insulin Development
7.1.1 Reformulating Insulin for Convenient Administration
7.1.1.1 Oral Insulin
7.1.1.2 Inhaled Insulin
7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
7.2 Next-Generation Insulin Submarket 2017-2028
7.2.1 Tresiba: Approved in the EU and Japan
7.2.1.1 Tresiba: Revenue Forecast 2017-2028
7.3 Next-Generation Insulin Submarket 2016-2027
7.3.1 Next-Generation Insulin Submarket Forecast 2016-2027
7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2017-2028
7.3.3 Next-Generation Insulin Submarket Restraints 2017-2028
7.3.3.1 Biosimilar Insulins are Available Since 2015
7.4 Oral Insulin Submarket 2017-2028
7.4.1 Oral Insulin Submarket Forecast 2017-2028
7.4.2 Oral Insulin: Submarket Drivers and Restraints 2017-2028
7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2017
7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
7.4.3.2 Oshadi Icp: Phase II Currently Recruiting
7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
7.4.3.5 Novo Nordisk: NN-1953
7.5 Ultra-Rapid Acting Insulin Submarket 2017-2028
7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2017-2028
7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2028?
7.5.2 Other Submarket Drivers and Restraints 2017-2028
7.5.3 Ultra-Rapid Acting Insulin Pipeline 2016
7.5.3.1 FlAsp (Novo Nordisk)
7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
7.5.3.3 Halozyme Therapeutics
7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
7.5.3.6 Adagio: A Second-Generation Inhaled Insulin
7.6 Ultra-Long Acting Insulin Submarket 2017-2028
7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2017-2028
7.6.2 Revenue Growth Driven by Uptake of Tresiba
7.6.3 Ultra-Long Acting Insulin Pipeline 2017
7.6.3.1 Toujeo: Sanofi’s Next-Generation Insulin Analogue
7.6.3.2 LAPS-Insulin
8. Next-Generation Developments for Other Recombinant Proteins 2017-2028
8.1 Defining Next-Generation for Other Recombinant Protein Sectors
8.1.1 Next-Generation Interferon Beta: Plegridy Revenue Forecast 2017-2028
8.1.1.1 Plegridy May Compete With Other Long-Acting Interferon Beta Therapies 2017-2028
8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2017
8.2 Next-Generation Recombinant Coagulation Factors 2017-2028
8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2017-2028
8.2.2 Submarket Drivers and Restraints 2017-2028
8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2017-2028
8.2.3.1 Fused Factors: Biogen Idec’s Eloctate and Alprolix
8.2.3.2 Baxter’s BAX 855
8.2.3.3 CSL Behring’s rlX-FP: Albumin-Bound Coagulation Factors
8.2.3.4 Bayer’s BAY94-9027
8.2.3.5 Novo Nordisk’s N8-GP for Haemophilia A
8.2.3.6 Novo Nordisk’s N9-GP for Haemophilia B
8.2.4 Gene Therapy as a New Treatment Option for Haemophilia
8.3 Next-Generation Growth Hormones 2017-2028
8.3.1 Next-Generation Growth Hormone Submarket Forecast 2017-2028
8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormone 2017-2028
8.3.3 Long-Acting Growth Hormones
8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
8.3.3.2 Prolor Biotech/OPKO Health
8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
8.3.3.4 Versartis: XTEN Technology for Half-Life Extension
8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin
9. Regenerative Medicine: Commercial Outlook 2017-2028
9.1 The Regenerative Medicine Submarket in 2017
9.1.1 Defining Regenerative Medicine
9.2 The Regenerative Medicine Submarket: Revenue Projections 2017-2028
9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2017-2028
9.3 The Stem Cell Therapies Submarket 2017-2028
9.3.1 Prochymal (Mesoblast) for GvHD
9.3.1.1 The Future for Prochymal: Approval in Crohn’s Disease?
9.3.1.2 A Note on Stem Cell Transplants
9.3.2 Stem Cell Therapies Submarket Forecast 2017-2028
9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2017-2028
9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy?
9.3.4 Stem Cell Therapies Late-Stage Pipeline 2017
9.3.4.1 Cx601 (TiGenix)
9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies
9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
9.3.4.4 StemEx (Gamida Cell)
9.4 Outlook for Tissue Engineering 2017-2028
9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair
9.4.1.1 Apligraf Leads the Wound Repair Submarket
9.4.1.2 Organogenesis Markets Apligraf and Dermagraft from 2014
9.4.2 Tissue Engineering Submarket Forecast 2017-2028
9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2017-2028
9.4.4 Future Developments in Cartilage Repair: Pipeline 2016
9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
9.4.5.1 Engineered Skin
9.4.5.2 Engineered Veins
9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
9.5 The Gene Therapies Submarket 2017-2028
9.5.1 Glybera Approved and Set for Launch in the EU
9.5.2 Gene Therapies Submarket: Revenue Projections 2017-2028
9.5.3 Glybera’s Approval Driving Submarket Growth Since 2014
9.5.4 There are More Than Five Gene Therapies in Late-Stage Development
9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer
9.5.4.2 TVEC (Amgen)
9.5.4.3 Generx (Cardium Therapeutics)
9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy
10. Next-Generation Biologics: Industry Trends 2017-2028
10.1 Next-Generation Biologics: Market Strengths 2017
10.2 Next-Generation Biologics: Market Weakness 2017
10.3 The Next-Generation Biologics Market: STEP Analysis 2017-2028
10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
10.3.1.2 Next-Generation Biologic Development in Emerging Markets
10.3.2 Technological Developments 2017-2028
10.3.3 Economic Pressures 2017-2028
10.3.3.1 High Drug Costs and Healthcare Spending
10.3.3.2 Limited Commercial Potential in Emerging Markets?
10.3.4 Political Issues: Regulatory Developments 2017-2028
10.4 Next-Generation Biologics: Development Trends 2017-2028
10.4.1 Improving Patient Convenience
10.4.2 Sustained Release Biologics: Pegylation and Beyond
10.4.3 Therapeutic Focus for Next-Generation Biologics
10.4.4 Next-Generation Biologics as Personalised Medicine
10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
10.5.1 Contract Manufacturers Invest to Follow Development Trends
10.6 Commercialising Next-Generation Biologics
10.6.1 Product Lifecycle Management for First Generation Biologics
10.6.2 Proving Benefit in Next-Generation Products
10.6.3 Biosimilars as a Challenger 2017-2028
10.7 Partnering for Next-Generation Biologic Development
10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
10.7.2 Most Development Platforms Stem from Small Biotechs
11. Conclusions from Our Research and Analysis
11.1 The Next-Generation Biologics Market Will Grow Strongly to 2028
11.2 Next-Generation Antibody Development Will Lead the Market
11.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
11.4 Leading Regional Markets
11.5 Challenges Remain in Developing and Commercialising Next-Generation Biologics
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Figures
Figure 1.1 Next-Generation Biologic Market Segmentation, 2017
Figure 3.1 Next-Generation Biologics: Market Shares (%) by Sector, 2017
Figure 3.2 Next-Generation Biologics Market: Revenue Forecast ($bn), 2017-2028
Figure 3.3 Next-Generation Biologics: Market Drivers, 2018-2028
Figure 3.4 Next-Generation Biologics: Market Restraints, 2017-2028
Figure 3.5 Next-Generation Biologics: Market Shares (%) by Sector, 2023
Figure 3.6 Next-Generation Biologics: Market Shares (%) by Sector, 2028
Figure 4.1 Next-Generation Biologics: Market Shares (%) by Country, 2017
Figure 4.2 Next-Generation Biologics: Market Shares (%) by Country, 2023
Figure 4.3 Next-Generation Biologics: Market Shares (%) by Country, 2028
Figure 4.4 US Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 4.5 Japanese Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 4.6 EU5 Nations: Next-Generation Biologics Submarket Shares (%), 2017
Figure 4.7 German Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 4.8 French Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 4.9 UK Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 4.10 Italian Next-Generation Biologics Submarket Forecast ($bn), 2017-2028
Figure 4.11 Spanish Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 4.12 Biosimilar Approvals in India, 2001-2015
Figure 4.13 Chinese Next-Generation Biologics Submarket Forecast ($bn) &AGR (%), 2017-2028
Figure 4.14 Indian Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 5.1 Next-Generation Antibodies: Submarket Shares (%) by Sector, 2017
Figure 5.2 Next-Generation Antibodies Submarket Forecast ($bn), 2017-2028
Figure 5.3 Antibody-Drug Conjugates: Submarket Shares (%) by Drug, 2017
Figure 5.4 Adcetris: Revenue Forecasts ($bn) & AGR (%), 2017-2028
Figure 5.4 Kadcyla Revenue Forecasts ($bn) & AGR (%), 2017-2028
Figure 6.1 Next-Generation Antibody Fragment and ALP Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 6.2 Next-Generation Antibody Fragment Submarket Forecast ($bn), 2017-2028
Figure 6.3 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2017-2028
Figure 7.1 Tresiba: Revenue Forecast ($bn), & AGR (%), 2017-2028
Figure 7.2 Next-Generation Insulin Submarket Revenue Forecast ($bn), 2017-2028
Figure 7.3 Diabetes: Proportion of Population Affected, 2016
Figure 7.4 Oral Insulin Submarket Forecast ($bn), 2017-2028
Figure 7.5 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2017-2028
Figure 7.6 Afrezza: Revenue Forecast ($bn), 2017-2028
Figure 7.7 Ultra-Long Acting Insulin Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 8.1 Plegridy: Revenue Forecast ($bn) & AGR (%), 2017-2028
Figure 8.2 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 8.3 Eloctate: Revenue Forecast ($bn), 2017-2028
Figure 8.4 Alprolix: Revenue Forecast ($bn), 2017-2028
Figure 8.5 Next-Generation Growth Hormones Submarket Forecast ($bn), 2017-2028
Figure 9.1 Regenerative Medicine: Submarket Shares (%) by Sector, 2016
Figure 9.2 Regenerative Medicine Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 9.3 Stem Cell Therapies Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 9.4 Tissue Engineering Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 9.5 Gene Therapies Submarket Forecast ($bn) & AGR (%), 2017-2028
Figure 10.1 Big Pharma Partnering Opportunities for Next-Generation Biologics Development, 2017
List of Tables
Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1997
Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1997
Table 3.1 Top Ten Bestselling Prescription Pharmaceuticals: Revenues ($bn), 2016
Table 3.2 Next-Generation Biologics Market: Revenues ($bn) & Market Share (%) by Sector, 2017
Table 3.3 Biological Drugs Market: Drivers and Restraints, 2017-2028
Table 3.4 Next-Generation Biologics Market: Overall Market Forecast and Revenue Forecasts ($bn), AGR (%), & CAGR (%) by Sector, 2017-2028
Table 3.5 Next-Generation Biologics: Market Shares (%) by Sector, 2018, 2023 and 2028
Table 4.1 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2017
Table 4.2 Next-Generation Biologics Market: Revenues ($bn), AGR (%), & CAGR (%) by National Submarket, 2017-2028
Table 4.2 Next-Generation Biologics Market: Revenues ($bn), AGR (%), & CAGR (%) by National Submarket, 2017-2028 (continued)
Table 4.3 Next-Generation Biologics: Revenue ($bn) & Market Shares (%) by National Submarket, 2023 and 2028
Table 4.4 National Incidence and Prevalence of Leading Indications Treated with Biologics (millions of patients), 2016
Table 4.5 Main Approval Dates for Next-Generation Biologics in Leading National Submarkets, 2003-2013
Table 4.6 US Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 4.7 Biosimilars Approved and Marketed in Japan, 2016
Table 4.8 Japanese Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 4.9 Next-Generation Biologics Submarkets in the EU5 Nations: Revenues ($bn) & Market Share (%) 2017
Table 4.10 German Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 4.11 France Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 4.12 UK Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 4.13 Italian Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 4.14 Spanish Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%) 2017-2028
Table 4.15 Chinese Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 4.16 Indian Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 5.1 Monoclonal Antibodies Submarket: Leading Drug Revenues ($bn), 2016
Table 5.2 Next-Generation Antibodies Submarket: Approved Drug Revenues ($bn), 2016
Table 5.3 Selected Clinical and Pre-Clinical ADC Platforms, 2016
Table 5.4 Selected Clinical and Pre-Clinical Engineered Antibody Platforms, 2016
Table 5.5 Next-Generation Antibodies Submarket: Revenues by Sector ($bn) & Market Share (%), 2017
Table 5.6 Next-Generation Antibodies Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%), & CAGR (%), by Sector, 2018-2028
Table 5.7 Next-Generation Antibodies Submarket: Drivers and Restraints, 2017-2028
Table 5.8 Antibody Drug Conjugates Submarket: Revenues ($bn) and Submarket Shares (%) by Drug, 2017
Table 5.9 Antibody-Drug Conjugates Submarket Forecast ($bn), AGR (%), & CAGR (%), 2017-2028
Table 5.10 Kadcyla and Adcetris: Revenue Forecasts ($bn), 2023-2028
Table 5.11 Antibody-Drug Conjugates Submarket: Drivers and Restraints, 2017-2028
Table 5.12 Selected Antibody-Drug Conjugates in Phase III Development, 2016
Table 5.13 Selected Antibody-Drug Conjugates in Phase II Development, 2016
Table 5.14 Selected Antibody-Drug Conjugates in Phase I Development, 2016
Table 5.15 Engineered Antibodies Submarket Forecast ($bn), 2017-2028
Table 5.16 Gazyva/Gazyvaro: Revenue Forecast ($bn), 2017-2022
Table 5.17 Engineered Antibodies Submarket: Drivers and Restraints, 2017-2028
Table 5.18 Selected Engineered Antibodies in Phase II and III Development, 2016
Table 5.19 Bispecific Antibodies Submarket Forecast ($bn), 2017-2022
Table 5.20 Bispecific Antibodies Submarket: Drivers and Restraints, 2017-2028
Table 5.21 Bispecific Antibodies in Phase I and II Development, 2016
Table 6.1 Selected Next-Generation Antibody Fragment Platforms, 2018
Table 6.2 Selected Antibody-Like Protein Platforms, 2017
Table 6.3 Next-Generation Antibody Fragment and ALP Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%) & CAGR (%), by Sector, 2017-2028
Table 6.4 Next-Generation Antibody Fragment and ALP Submarket: Drivers and Restraints, 2017-2028
Table 6.6 Next-Generation Antibody Fragment Submarket Forecast ($bn), AGR (%) & CAGR (%), 2017-2028
Table 6.8 Next-Generation Antibody Fragment Submarket: Clinical Pipeline, 2017
Table 6.9 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2018-2028
Table 6.10 Next-Generation Antibody-Like Protein Submarket: Clinical Pipeline, 2016
Table 7.1 Tresiba: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2017-2028
Table 7.2 Next-Generation Insulin Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2017-2028
Table 7.3 Next-Generation Insulin Submarket: Drivers and Restraints, 2017-2028
Table 7.4 Diabetes: Prevalence and Proportion of Population Affected, 2016
Table 7.5 Leading Insulin Analogues: US and EU Patent Expiries, 2013-2019
Table 7.6 Oral Insulin Submarket Forecast ($bn), 2023-2028
Table 7.7 Oral Insulin Submarket: Drivers and Restraints, 2017-2028
Table 7.8 Oral Insulin: Selected Pre-Clinical and Clinical-Stage Pipeline, 2017
Table 7.9 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2017-2028
Table 7.10 Ultra-Rapid Acting Insulin Submarket: Drivers and Restraints, 2017-2028
Table 7.11 Ultra-Rapid Acting Insulin: Pre-Clinical and Clinical-Stage Pipeline, 2016
Table 7.12 Afrezza: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2017-2028
Table 7.13 Ultra-Long Acting Insulin Forecast ($bn) AGR (%) & CAGR (%), 2018-2028
Table 7.14 Ultra-Long Acting Insulin Submarket: Drivers and Restraints, 2017-2028
Table 7.15 Selected Ultra-Long Acting Insulin: Clinical-Stage Pipeline, 2017
Table 8.1 Plegridy: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2028
Table 8.2 Recombinant Coagulation Factor Half-Lives and Target Populations, 2017
Table 8.3 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn), AGR (%) & CAGR (%), 2017-2028
Table 8.4 Next-Generation Recombinant Coagulation Factors Submarket: Drivers and Restraints, 2017-2028
Table 8.5 Eloctate: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2017-2028
Table 8.5 Long-Acting Recombinant Factors VIII and IX in Late-Stage Clinical Development, 2017
Table 8.6 Alprolix: Revenue Forecast ($bn), 2017-2022
Table 8.7 Next-Generation Growth Hormones Submarket Forecast ($bn), 2017-2022
Table 8.8 Next-Generation Growth Hormones Submarket: Drivers and Restraints, 2017-2028
Table 8.9 Selected Next-Generation Growth Hormones in Clinical Development, 2016
Table 9.1 Regenerative Medicine Submarket: Revenues by Sector ($bn) & Submarket Share (%) 2017
Table 9.2 Regenerative Medicine Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%) and CAGR (%) by Sector, 2018-2028
Table 9.3 Regenerative Medicine Submarket: Drivers and Restraints, 2017-2028
Table 9.4 Stem Cell Therapies Submarket Forecast ($bn), AGR (%) & CAGR (%), 2017-2022
Table 9.5 Stem Cell Therapies Submarket: Drivers and Restraints, 2017-2028
Table 9.6 Selected Stem Cell Therapies in Phase II and III Clinical Trials, 2017
Table 9.7 Selected Stem Cell Therapies in Phase I/II Development, 2017
Table 9.8 Tissue Engineering Submarket Forecast ($bn), AGR (%) & CAGR (%), 2017-2028
Table 9.9 Tissue Engineering Submarket: Drivers and Restraints, 2017-2028
Table 9.10 Gene Therapies Submarket Forecast ($bn), AGR (%) & CAGR (%), 2017-2028
Table 9.11 Gene Therapies Submarket: Drivers and Restraints, 2017-2028
Table 9.12 Gene Therapies in Phase II and III Clinical Trials, 2017
Table 10.1 Next-Generation Biologics: STEP Analysis, 2017-2028
Table 10.2 Selected CMO Investments in Next-Generation Biologics, to 2017
Table 12.1 Next-Generation Biologics Market: Submarket Forecasts ($bn) and Market Shares (%), 2017, 2023 and 2028
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
